Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Entrada Therapeutics Inc (TRDA) has an earnings forecast score of 8.50 and is ranked 109th in the Biotechnology & Medical Research industry. Analysts project a target price of $16.50 for TRDA, with an expected revenue of $5.26M for the next quarter. Most analysts recommend a "Buy" for Entrada Therapeutics Inc, though investors should conduct their own research.
HC Wainwright Analysts Lower Earnings Estimates for TRDA
HC Wainwright analysts have reduced their Q3 2026 earnings per share estimates for Entrada Therapeutics (NASDAQ:TRDA) to a loss of $1.18, maintaining a "Neutral" rating. The company's recent quarterly results missed expectations, reporting a $1.01 loss per share against an anticipated $0.97 loss, and revenue of $0.90 million versus a $2.32 million consensus. Despite high institutional ownership, analyst sentiment remains mixed with a consensus "Hold" rating and a target price of $17.50, significantly higher than its recent trading price of $7.04.
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $73,458.00 in Stock
Entrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar sold 10,494 shares of the company's stock for $73,458, reducing his stake by 0.37%. This sale is part of several recent transactions by Parmar. The company's stock traded up 1.2% to $6.95, despite missing analyst estimates for its quarterly earnings and revenue.
5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620
5AM Ventures V sold 62,811 common shares of Entrada Therapeutics on August 6-7, 2026, for a total value of $431,620. Following these sales, their direct stake in the company decreased to 2,783,781 shares, while 5AM Opportunities I held an indirect stake of 1,093,313 shares.
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock
5am Ventures V, L.P. sold $431,829 worth of Entrada Therapeutics Inc. stock through multiple transactions on August 6 and 7, 2026. The sales occurred at prices ranging from $6.85 to $7.0 per share. Despite a 32% year-to-date decline and trading 58% below its 52-week high, InvestingPro analysis suggests the company is undervalued, though it is quickly burning through cash.
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com
5am Ventures V, L.P., a significant owner of Entrada Therapeutics, Inc. (NASDAQ:TRDA), sold common stock worth $431,829 across multiple transactions on August 6 and 7, 2026, at prices between $6.85 and $7.0 per share. Despite a 32% year-to-date decline in the stock, InvestingPro analysis indicates it may be undervalued, though the company is rapidly burning through cash. Entrada Therapeutics also received clearance to proceed with a higher dose in its ELEVATE-45-201 study, marking a key development in its clinical programs.
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $358,371.45 in Stock
Entrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar sold 52,317 shares of the company's stock for $358,371.45 on August 7th, reducing his ownership by 1.84%. This sale is part of a series of recent transactions by Parmar, totaling significant amounts in August and July. The company's stock is trading near $6.95, and it recently reported a quarterly loss and missed revenue expectations, leading analysts to hold an average "Hold" rating with a target price of $17.50.
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com
5am Ventures V, L.P., a major stakeholder in Entrada Therapeutics Inc. (NASDAQ:TRDA), sold $431,829 worth of common stock across multiple transactions on August 6 and 7, 2026, with prices ranging from $6.85 to $7.00 per share. Despite the stock's year-to-date decline, InvestingPro analysis suggests it remains undervalued, though the company is rapidly burning cash. Separately, Entrada Therapeutics received clearance to proceed with a higher dose in its ELEVATE-45-201 study, marking a significant step in its clinical programs.
5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620
5AM Ventures V has reported the sale of 62,811 Entrada Therapeutics common shares between August 6-7, at weighted-average prices of $7 and $6.85, totaling approximately $431,620. Following these transactions, their direct stake in Entrada Therapeutics decreased to 2,783,781 shares. An indirect stake of 1,093,313 shares is held by 5AM Opportunities I.
Entrada Therapeutics (TRDA): 5AM Ventures-linked funds sell 62,811 shares, retain over 1.09M
Investment funds associated with 5AM Ventures, a major stockholder in Entrada Therapeutics (TRDA), sold a total of 62,811 shares of common stock on August 6-7, 2026. The sales were executed at weighted average prices of $7.00 and $6.85 per share. Following these transactions, an affiliated fund, 5AM Opportunities I, L.P., still holds 1,093,313 shares of Entrada Therapeutics common stock indirectly.
Entrada Therapeutics, Inc. (TRDA) stock price, news, quote and history
This page provides comprehensive information on Entrada Therapeutics, Inc. (TRDA), including its current stock price, trading activity, historical data, and company profile. It details the company's financials, performance overview against the S&P 500, earnings trends, and analyst ratings, offering a complete snapshot for investors. The article also lists similar companies for comparison and highlights trending tickers.
Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA)
This article highlights two healthcare stocks, Insulet (PODD) and Entrada Therapeutics Inc (TRDA), which have received bullish sentiments from analysts. Steven Lichtman of William Blair maintained a Buy rating on Insulet, while Myles Minter, also from William Blair, maintained a Buy rating on Entrada Therapeutics Inc. Both companies show significant upside potential according to analyst consensus.
Entrada Therapeutics, Inc. (TRDA) Stock Price, News, Quote & History
This page provides comprehensive financial data for Entrada Therapeutics, Inc. (TRDA), a clinical-stage biopharmaceutical company. It includes real-time stock price, historical data, key statistics, performance overview against the S&P 500, earnings trends, analyst insights, and valuation measures. The company focuses on developing genetic medicines for neuromuscular and inherited retinal diseases using its Endosomal Escape Vehicle technology.
Entrada Therapeutics, Inc. (TRDA) stock price, news, quote and history
This article provides a comprehensive overview of Entrada Therapeutics, Inc. (TRDA), a clinical-stage biopharmaceutical company. It covers the company's stock performance, key financial metrics, recent news, analyst ratings, and a description of its focus on developing new medicines for neuromuscular and inherited retinal diseases. The company's stock closed at $6.87, with pre-market activity showing a rise to $7.09.
Entrada Therapeutics Releases Q2 2026 Financial Results
Entrada Therapeutics, Inc. reported a net loss of $42.8 million for the first half of 2026, reflecting continued investment in its pipeline of intracellular therapeutics. The company posted a loss of $1.01 per share, with revenue totaling $898,000, a 54.0% decrease from H1 2025. These results highlight the capital-intensive nature of advancing therapeutic candidates through clinical development as a pre-commercial biotech firm.
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Entrada Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The brief report indicates the company's financial performance for the specified period. The full details are available through Refinitiv and other news sources on TradingView.
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Entrada Therapeutics announced its second-quarter 2026 financial results, highlighted by upcoming clinical data readouts for its Duchenne muscular dystrophy (DMD) programs and progress in its myotonic dystrophy type 1 (DM1) partnership with Vertex. The company reported a cash position of $223.0 million, sufficient to fund operations into the third quarter of 2027, and a net loss of $42.8 million for the quarter. Multiple data readouts are anticipated throughout late 2026 and early 2027 for its ELEVATE-44-201 and ELEVATE-45-201 studies, alongside continued advancement of its preclinical pipeline in ocular and metabolic diseases.
Entrada Therapeutics (NASDAQ: TRDA) details $82M H1 loss and $223M cash runway
Entrada Therapeutics reported a net loss of $42.8 million for Q2 2026 and $82.5 million for the first half of 2026, with collaboration revenue declining due to the completion of major research milestones. The company maintains a strong cash position of $223.0 million, expected to fund operations into Q3 2027. Entrada also highlighted positive clinical data from its ELEVATE-44-201 trial for Duchenne muscular dystrophy, showing dystrophin increases and functional improvements, and provided updates on other pipeline programs.
Entrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases
Entrada Therapeutics announced upcoming clinical data catalysts for 2026 across Duchenne muscular dystrophy and myotonic dystrophy type 1. The company's ENTR-601-44 Phase 1/2 Cohort 1 showed significant improvement in Time to Rise and no serious adverse events. Future data releases include Cohort 1 open-label function and safety data by year-end 2026, Cohort 2 data in Q1 2027, and Vertex's VX-670 data in H2 2026.
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) reported a narrower-than-expected Q2 loss of $1.01 per share, beating the Zacks Consensus Estimate of a $1.16 loss. The company also surpassed revenue estimates, posting $0.9 million for the quarter, although this was lower than the $1.95 million reported a year ago. Despite outperforming EPS estimates in three of the last four quarters, TRDA shares have decreased by nearly 30% year-to-date.
Entrada Therapeutics (Nasdaq: TRDA) reports Q2 2026 results and sets DMD, DM1 data timeline
Entrada Therapeutics (TRDA) reported a Q2 2026 net loss of $42.8 million and outlined upcoming clinical milestones for its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. The company held $223.0 million in cash, expected to fund operations into Q3 2027, and anticipates multiple data readouts between late 2026 and mid-2027 for its ELEVATE studies and the VX-670 collaboration with Vertex.
Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary
Entrada Therapeutics, Inc. reported its Q2 2026 results, showing collaboration revenue of $898K and a diluted loss per share of ($1.01). The company highlighted clinical advancements in its DMD programs, progress in its collaboration with Vertex, and an expected funding runway into Q3 2027 with $223M in cash resources.
Entrada Therapeutics reports Q2 2026 results: $223.0M cash; Q2 net loss $42.8M
Entrada Therapeutics reported its second-quarter 2026 financial results, showing a net loss of $42.8 million and cash, cash equivalents, and marketable securities totaling $223.0 million. The company expects its cash reserves to fund operations into Q3 2027. Entrada also provided updates on its clinical programs, including progress in its ELEVATE-44-201 and ELEVATE-45-201 studies, regulatory advancements for ENTR-601-50 and ENTR-601-51, and developments in its collaboration with Vertex Pharmaceuticals.
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Entrada Therapeutics reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) clinical programs. The company anticipates several key data readouts in late 2026 and early 2027 for its ELEVATE-44-201 and ELEVATE-45-201 studies, as well as data from its collaboration with Vertex on VX-670 for DM1. Entrada Therapeutics maintains a strong cash position expected to fund operations into Q3 2027.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Recommendation of "Hold" from Brokerages
Entrada Therapeutics, Inc. (NASDAQ:TRDA) has received an average "Hold" recommendation from brokerages, based on a mix of sell, hold, and buy ratings, with an average 12-month price target of $17.50. The company's shares opened at $7.26 and have traded between $4.93 and $16.45 over the past year. Despite beating EPS expectations, Entrada's revenue fell short of consensus estimates, and insiders have sold shares while institutional investors maintain a significant stake.
5am Ventures V sells $807,027 of Entrada Therapeutics stock
5am Ventures V, a significant owner and director of Entrada Therapeutics (NASDAQ:TRDA), recently sold shares worth $807,027. These transactions occurred on July 30 and July 31, 2026, with share prices ranging from $6.85 to $6.93, even though TRDA stock has recently surged by 24.5%. The company is also progressing with its Duchenne Muscular Dystrophy study and plans to release topline results from another clinical study soon.
Entrada Therapeutics director, 10% owner Kush Parmar disposes of $807,529 in common shares
Entrada Therapeutics director and 10% owner Kush Parmar sold 116,474 common shares on July 30-31, totaling $807,529. These transactions reduced 5AM Ventures V's stake to 2,846,592 shares, while 5AM Opportunities I held 1,093,313 shares afterward. This news brief was generated by AI based on information from the U.S. SEC's EDGAR system.
Entrada Therapeutics director Kush Parmar sells $807,027 in shares
Kush Parmar, a director and 10% owner of Entrada Therapeutics (NASDAQ:TRDA), recently sold $807,027 worth of company shares through 5AM Ventures V, L.P., across two transactions on July 30 and 31, 2026. The sales occurred as TRDA stock surged 24.53% over the past week and traded above its InvestingPro Fair Value estimate. The company also recently received clearance to escalate dosage in its ELEVATE-45-201 study and is set to report topline results for its ENTR-601-44 clinical study soon.
5am Ventures V sells $807,027 of Entrada Therapeutics stock
5AM Ventures V, L.P., a significant owner and director of Entrada Therapeutics (NASDAQ:TRDA), recently sold shares worth $807,027. These transactions occurred over two days, with shares sold at prices between $6.85 and $6.93, even as the stock has surged 24.5% in the past week to $7.26. The company is also progressing with its Duchenne Muscular Dystrophy study and is expected to release topline results from another clinical study soon.
Form 4 Entrada Therapeutics Inc For: 4 August By Investing.com
This article from Investing.com is a minimal announcement regarding a Form 4 filing for Entrada Therapeutics Inc, dated August 4. It provides the stock symbol TRDA and notes a -2.20% change. The content primarily consists of navigation, advertisements, and market data rather than detailed information about the Form 4 filing itself.
Entrada Therapeutics (TRDA) holder sells shares, still reports 1.09M stake
5AM Ventures V, L.P., a ten percent shareholder of Entrada Therapeutics (TRDA), reported selling a total of 116,474 shares of common stock on July 30-31, 2026, with transactions occurring at a weighted average price of $6.93 per share. Despite these sales, affiliated entity 5AM Opportunities I, L.P. still indirectly holds 1,093,313 shares of Entrada Therapeutics as of July 30, 2026. The transaction details were disclosed in a Form 4 SEC filing, which also identifies other related reporting persons and clarifies beneficial ownership.
Liquidity Mapping Around (TRDA) Price Events
This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA) using AI models, highlighting a positive near-term sentiment within a long-term strength context despite a mid-term weak bias. It identifies key support and resistance levels and outlines three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also points to an exceptional 171.0:1 risk-reward setup targeting a 51.4% gain.
Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Entrada Therapeutics Inc (TRDA), noting its current valuation score of 6.99 within the Biotechnology & Medical Research industry. It details the company's current P/E ratio of -1.70, highlighting its significant deviation from recent highs and lows. The analysis also mentions that P/B, P/S, and P/CF relevant data have not yet been disclosed by the company.
TRDA|Entrada Therapeutics Inc|Price:6.550|Chg%:+0.720
This article provides a comprehensive stock analysis of Entrada Therapeutics Inc (TRDA), highlighting its healthy fundamentals, significant growth potential, and "Buy" ratings from multiple analysts with a highest price target of $18.75. Despite a recent weak stock market performance, the company exhibits strong underlying financials and is currently in a growing phase. Its stock is considered fairly valued and is trading sideways, making it suitable for range-bound swing trading according to the analysis.
Entrada Therapeutics Inc (TRDA) Institutional Confidence
Entrada Therapeutics Inc (TRDA) has an institutional shareholding score of 7.00, placing it 80th in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 80.65%, showing a 2.92% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.56% of outstanding shares.
Entrada Therapeutics, Inc. Revenue Breakdown – NASDAQ:TRDA
Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported revenue of $25.41 million USD last year. The primary source of this revenue was its Endosomal Escape Vehicle Therapeutics segment, which generated $25.42 million USD, a significant decrease from $210.78 million USD in the previous year. The United States was the largest geographical contributor, matching the segment's revenue.
Entrada Therapeutics Inc (TRDA) Cash Flow
This article provides a detailed historical overview of Entrada Therapeutics Inc's (TRDA) cash flow statements, covering quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics like net income, capital expenditures, and free cash flow, alongside answers to frequently asked questions about these financial concepts. The data presented shows various fluctuations in the company's cash generation and utilization over several fiscal quarters and years.
Entrada Therapeutics Inc (TRDA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Entrada Therapeutics Inc (TRDA) shareholder structure, listing major shareholders, their equity proportions, and changes in their holdings. It also categorizes shareholders by type (e.g., Investment Advisor, Hedge Fund, Venture Capital) and presents institutional shareholding trends over several quarters. Finally, it lists relevant ETFs that hold TRDA shares.
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Entrada Therapeutics Inc (TRDA), focusing on business segments, regional revenue, and profit contribution. As of the report, relevant data for FY2025 across all quarters and FY2023Q2 have not been disclosed by the company. The currently available regional data indicates $25.42 million from the United States with a 0.00% proportion, suggesting incomplete or pending disclosure.
Entrada Therapeutics Inc (TRDA) Balance Sheet
This article provides the quarterly and annual balance sheets for Entrada Therapeutics Inc (TRDA), allowing users to analyze its financial health. It includes detailed financial data categories such as total equity, cash, investments, receivables, liabilities, and shareholders' equity. The data spans several fiscal quarters and years, offering a comprehensive overview of the company's financial performance and structure.
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis
Entrada Therapeutics Inc (TRDA) has a financial score of 6.02, ranking 298 out of 386 in its industry, indicating stable financial status but low operating efficiency. The company reported a significant year-over-year revenue decrease of 95.74% and a net profit decrease of 128.93% in its latest quarter. Key financial metrics such as cash and cash equivalents, total assets, liabilities, and free cash flow have not yet been disclosed by the company, impacting detailed analysis of its quality of earnings, operational efficiency, growth potential, and shareholder returns.
Why (TRDA) Price Action Is Critical for Tactical Trading
This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It provides AI-generated trading strategies including position, momentum breakout, and risk hedging, along with detailed support, resistance, and signal strength across different time horizons. The analysis emphasizes the importance of price action for tactical trading decisions.
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10
Roth MKM has reiterated its Buy rating for Entrada Therapeutics (TRDA.US) and maintained its target price at $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Why (TRDA) Price Action Is Critical for Tactical Trading
This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA) using AI models to provide tactical trading strategies based on different risk profiles and holding periods. It highlights weak near-term sentiment but strong mid and long-term support signals, offering specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies. The analysis emphasizes the importance of price action for tactical trading decisions.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Entrada Therapeutics, Inc. (NASDAQ: TRDA) on behalf of investors. This investigation follows a significant stock price drop of 57.27% on May 7, 2026, after the company announced "positive" Phase 1/2 clinical study results that showed a very small increase in dystrophin production, deemed insufficient to make the drug competitive. The law firm is encouraging affected investors to contact them for more information and to assist in the investigation.
Understanding Momentum Shifts in (TRDA)
This article analyzes Entrda Therapeutics Inc. (NASDAQ: TRDA) using AI models, highlighting strong sentiment across all horizons supporting an overweight bias. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths and support/resistance levels.
Price to book forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA
This article displays the "Price to book forward" metric for Entrada Therapeutics, Inc. (NASDAQ: TRDA). It appears to be a financial data point presented within the TradingView platform, with no additional textual analysis or details provided. The content is minimalist, focusing solely on the presentation of this specific financial ratio for the company.
Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA
This article provides a brief financial overview for Entrada Therapeutics, Inc. (NASDAQ: TRDA), focusing on its forward price-to-earnings ratio. The content primarily lists navigation and platform features of TradingView, where this financial data is presumably presented, rather than offering detailed analysis or specific figures.
Price to sales forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA
This page provides financial information for Entrada Therapeutics, Inc. (NASDAQ: TRDA) on TradingView, specifically focusing on its price-to-sales forward ratio. It also lists various features and services offered by TradingView, including market data, analytical tools, community features, and business solutions.
Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA)
This article provides an overview of Entrada Therapeutics, Inc. (NASDAQ: TRDA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and past financial results, alongside information on employee count and EBITDA.
